# FORM 4

#### UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL					
MB Number:	3235-0287				
stimated average burden					
ours per response	0.5				

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the

Instruc	tion 1(b).			III v Cour	none comp	uny 110	01 17 10							
Print or Typ	e Responses	s)												
Name and Address of Reporting Person *  Cavalier David			2. Issuer Name and Ticker or Trading Symbol Anixa Biosciences Inc [ANIX]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  X Director 10% Owner						
(Last) (First) (Middle) 3150 ALMADEN EXPRESSWAY, SUITE 250			3. Date of Earliest Transaction (Month/Day/Year) 10/08/2018					Officer (give	title below)		er (specify belo	v)		
			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person						
	E, CA 9511		(201.)											
(City	)	(State)	(Zip)	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										
1.Title of Se (Instr. 3)	ecurity		Date (Month/Day/Year)	2A. Deemed Execution Datany (Month/Day/Y	te, if Code (Instr.	nsaction 8)		ties Acqui isposed of 4 and 5)	(D) (	5. Amount of S Owned Follow Γransaction(s) (Instr. 3 and 4)		d	Ownership Form:	Beneficial Ownership
					Coo	le V	Amount	(A) or (D)	Price				(I) (Instr. 4)	
Reminder: F	Report on a se	eparate line for each	n class of securities	beneficially or	wned directl	y or ind	rectly.							
						con	tained in	this form	are	ne collection not required ralid OMB co	to respon	d unless th		1474 (9-02)
				Derivative Sec e.g., puts, call						Owned				
1. Title of	2.	3. Transaction	3A. Deemed	4.	5. Number	_	e Exercisab		7. Titl	e and	8. Price of	9. Number o		11. Natur
Security		Date (Month/Day/Year)		Code	Derivative		ation Date th/Day/Yea	r)	Amou Under	lying	Security	Derivative Securities	Form of	of Indirection
(Instr. 3)	Price of Derivative Security		(Month/Day/Year		Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	f		1	Securi (Instr.	ties 3 and 4)	(Instr. 5)	Beneficially Owned Following Reported Transactions (Instr. 4)	Security Direct (I or Indire	O) ct

Date

Exercisable Date

<u>(2)</u>

Expiration

10/08/2028

Title

Common

Stock

Amount or Number

45,000

\$ 0

45,000

D

of Shares

### **Reporting Owners**

\$ 5.29

Employee Stock

Option

(Right to Buy) (1)

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Cavalier David 3150 ALMADEN EXPRESSWAY SUITE 250 SAN JOSE, CA 95118	Х					

10/08/2018

### **Signatures**

/s/ David Cavalier	10/09/2018
**Signature of Reporting Person	Date

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Code

A

(A) (D)

45,000

- (1) Right-To-Buy, granted under the Anixa Biosciences, Inc. 2010 Share Incentive Plan.
- $\textbf{(2)} \ The \ options \ vest \ and \ become \ exercisable \ in \ twelve \ (12) \ equal \ monthly \ installments \ beginning \ October \ 31, \ 2018.$

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.